Skip to main content

PRESS ROOM

PSYCHECEUTICAL IN THE NEWS

Psycheceutical’s Topical PTSD Drug Poised for Human Trials

Read Feature

Psycheceutical Developing The First Ever Topical Psychedelic Cream To Treat PTSD

Read Feature

Psycheceutical Listed as 1 of 7 Psychedelic Stocks to Watch

Shark Tank’s Kevin Harrington Invests In Psychedelics Company Psycheceutical

Read Feature

Kevin Harrington Becomes The Latest ‘Shark Tank’ Judge To Enter The Psychedelics Space

Read Feature

Psycheceutical Announces Julian Bailes, M.D. as Principal Medical Advisor

Read Feature

Psycheceutical Bioscience, Inc. Announces Medical Advisory Board

Read Feature

Armed With Two Patents, Psycheceutical Plans To Transform Psychedelic Drug Delivery

Read Feature

Psycheceutical Licenses New Delivery Technologies For Psychedelic Medicines

Read Feature

Biotech Company Earns Two Patents for Targeted Delivery of Psychedelic Medicines

Read Story

Novel Psychedelic Treatment Approach Bypasses Hallucinogenic Effects to Allow Widespread Adoption

Read Story

Psychedelic Business Spotlight: Psycheceutical, Inc., Announces Exclusive License of Two Major Patents

Read Story

PODCASTS

Chad Harman, CEO of Psycheceutical, Sits in the Psychedelic Invest Investor Hotseat

Psycheceutical: Frontiers of Treatment with Dr. Thomas Cabell and Chad Harman

Psycheceutical’s Kaia Roman on the NuroFlex Podcast

Psycheceutical’s Zappy Zapolin On The Psychedelic Invest Podcast

Psycheceutical CEO, Chad Harman, On The Street Smart Podcast

PRESS RELEASES

MEDIA CONTACT

Kaia Roman

VP, Strategy & Communications

kaia.roman@psycheceutical.com
Contact